{
    "nctId": "NCT00992706",
    "briefTitle": "F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer",
    "officialTitle": "Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Palmar-plantar Erythrodysesthesia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 91,
    "primaryOutcomeMeasure": "Palmar-plantar erythrodysesthesia (PPE, hand-foot syndrome, HFS) grade \u2265 2",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of metastatic breast cancer\n\n  * No cutaneous metastases on hands or feet\n* Pegylated liposomal doxorubicin hydrochloride monotherapy is indicated according to the local investigator\n\n  * Planned dose at least 10 mg/m\\^2 per week\n* No sign of palmar-plantar erythrodysesthesia (PPE) at study entry\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0-2\n* Able to apply topical medication (cream) or provide for another person to apply cream\n* Not pregnant or breastfeeding\n* Fertile patients must use effective contraception during trial participation and for 1 month after completion\n* Negative pregnancy test\n* Compliant and geographically proximal in order to allow proper evaluation and follow-up\n* No dermatologic conditions (e.g., psoriasis) that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment\n* No known allergy or hypersensitivity to F511 cream\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 30 days since prior and no concurrent treatment with other experimental drugs or anticancer therapy\n* More than 30 days since prior and no concurrent treatment on another clinical trial\n* No concurrent local use of other ointments or creams for hands or feet other than Excipial Repair\u00ae",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}